Effects of Marijuana on Symptoms of OCD
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 21 - 55 |
| Updated: | 3/15/2019 |
| Start Date: | October 1, 2017 |
| End Date: | April 2019 |
| Contact: | Marissa Raskin, B.S. |
| Email: | Marissa.Raskin@nyspi.columbia.edu |
| Phone: | 646-774-8062 |
Effects of Marijuana on Symptoms of Obsessive-Compulsive Disorder
The purpose of this pilot research study is to test whether certain components of the
marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD.
Specifically, patients enrolled in the study will smoke marijuana containing different
concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the
brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Neither
compound is currently FDA-approved for treating OCD.
marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD.
Specifically, patients enrolled in the study will smoke marijuana containing different
concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the
brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Neither
compound is currently FDA-approved for treating OCD.
Inclusion Criteria:
- Age 21-55
- Physically healthy
- Diagnosed with OCD
- Current marijuana user
- Women of childbearing potential must be using an effective form of birth control
- Not currently taking psychotropic medications
- Ability to provide informed consent
Exclusion Criteria:
- History of any significant medical condition that may increase the risk of
participation
- Females who are pregnant or nursing
- If female, not pregnant
- Current or lifetime history of psychiatric disorders other than OCD that may increase
the risk of participation
- Current substance use disorder
- Severe depression or positive urine toxicology (other than THC) at screening, or any
adverse reaction to a cannabinoid
- Patients who are seeking treatment for substance abuse
- Patients who are planning to begin a course of cognitive-behavioral therapy within 8
weeks of beginning the study
We found this trial at
1
site
1051 Riverside Dr
New York, New York 10032
New York, New York 10032
646-774-5000
Phone: 646-774-8062
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials
